Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed J Kuijper

Showing results (161-170 of 250) with videos related to

Pageof 25
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosisMartijn P Bauer, Marjolein P M Hensgens, Mark A Miller, et al.
Emerging Infectious Diseases|May 18, 2006
Clostridium difficile ribotype 027, toxinotype III, the NetherlandsEd J Kuijper, Renate J van den Berg, Sylvia Debast, et al.
FEBS Letters|November 3, 2015
Clostridium difficile secreted Pro-Pro endopeptidase PPEP-1 (ZMP1/CD2830) modulates adhesion through cleavage of the collagen binding protein CD2831Paul J Hensbergen, Oleg I Klychnikov, Dennis Bakker, et al.
Proceedings. Biological Sciences|April 10, 2019
Relevance of heterokaryosis for adaptation and azole-resistance development in Aspergillus fumigatusJianhua Zhang, Eveline E Snelders, Bas J Zwaan, et al.
The Journal of Antimicrobial Chemotherapy|May 21, 2019
Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trialGeert H Groeneveld, Tanny J van der Reyden, Simone A Joosten, et al.
Lancet (London, England)|November 19, 2010
Clostridium difficile infection in Europe: a hospital-based surveyMartijn P Bauer, Daan W Notermans, Birgit H B van Benthem, et al.
Antimicrobial Resistance and Infection Control|January 30, 2021
Simultaneous detection and ribotyping of Clostridioides difficile, and toxin gene detection directly on fecal samplesTessel M van Rossen, Joffrey van Prehn, Alex Koek, et al.
Open Forum Infectious Diseases|July 28, 2022
Transmission of Antibiotic-Susceptible <i>Escherichia coli</i> Causing Urinary Tract Infections in a Fecal Microbiota Transplantation Recipient: Consequences for Donor Screening?Karuna E W Vendrik, Tim G J de Meij, Arend Bökenkamp, et al.
Gastroenterology|June 14, 2021
Fecal Microbiota Transplantation Influences Procarcinogenic Escherichia coli in Recipient Recurrent Clostridioides difficile PatientsSam Nooij, Quinten R Ducarmon, Jeroen F J Laros, et al.
Antimicrobial Resistance and Infection Control|April 10, 2022
Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017-2019Cornelia C H Wielders, Leo M Schouls, Sjoukje H S Woudt, et al.
Pageof 25

Showing results (161-170 of 250) with videos related to

Sort By:
Pageof 25
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 4, 2012
Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosisMartijn P Bauer, Marjolein P M Hensgens, Mark A Miller, et al.
Emerging Infectious Diseases|May 18, 2006
Clostridium difficile ribotype 027, toxinotype III, the NetherlandsEd J Kuijper, Renate J van den Berg, Sylvia Debast, et al.
FEBS Letters|November 3, 2015
Clostridium difficile secreted Pro-Pro endopeptidase PPEP-1 (ZMP1/CD2830) modulates adhesion through cleavage of the collagen binding protein CD2831Paul J Hensbergen, Oleg I Klychnikov, Dennis Bakker, et al.
Proceedings. Biological Sciences|April 10, 2019
Relevance of heterokaryosis for adaptation and azole-resistance development in Aspergillus fumigatusJianhua Zhang, Eveline E Snelders, Bas J Zwaan, et al.
The Journal of Antimicrobial Chemotherapy|May 21, 2019
Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trialGeert H Groeneveld, Tanny J van der Reyden, Simone A Joosten, et al.
Lancet (London, England)|November 19, 2010
Clostridium difficile infection in Europe: a hospital-based surveyMartijn P Bauer, Daan W Notermans, Birgit H B van Benthem, et al.
Antimicrobial Resistance and Infection Control|January 30, 2021
Simultaneous detection and ribotyping of Clostridioides difficile, and toxin gene detection directly on fecal samplesTessel M van Rossen, Joffrey van Prehn, Alex Koek, et al.
Open Forum Infectious Diseases|July 28, 2022
Transmission of Antibiotic-Susceptible <i>Escherichia coli</i> Causing Urinary Tract Infections in a Fecal Microbiota Transplantation Recipient: Consequences for Donor Screening?Karuna E W Vendrik, Tim G J de Meij, Arend Bökenkamp, et al.
Gastroenterology|June 14, 2021
Fecal Microbiota Transplantation Influences Procarcinogenic Escherichia coli in Recipient Recurrent Clostridioides difficile PatientsSam Nooij, Quinten R Ducarmon, Jeroen F J Laros, et al.
Antimicrobial Resistance and Infection Control|April 10, 2022
Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017-2019Cornelia C H Wielders, Leo M Schouls, Sjoukje H S Woudt, et al.
Pageof 25